Research and Markets has announced the addition of the "GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 184.108.40.206) - Pipeline Review, H2 2016" report to their offering.
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 220.127.116.11) is a GTPase encoded by the KRAS gene. It plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.
The GTPase KRas pipeline target constitutes close to 17 molecules, out of which approximately 12 molecules are developed by Companies and the remaining by Universities/Institutes. The molecules developed by Companies in Preclinical and Discovery stages are 2 and 10, respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Our latest report GTPase KRas - Pipeline Review, H2 2016, outlays comprehensive information on targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in GTPase KRas targeted therapeutics development, and features dormant and discontinued projects and the latest news and press releases.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/gmpt7j/gtpase_kras_kras.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161010006047/en/Business Wire
Last updated on: 10/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.